A gene therapy from Voyager Therapeutics (VYGR) delivered surgically into the brains of patients with advanced Parkinson’s disease reduced their need for standard Parkinson’s medications and improved motor function, according to results from a small, early-stage clinical trial reported Wednesday.

Unlike most gene therapies for inherited disease in clinical development, the Voyager treatment does not aim to cure Parkinson’s — because nothing yet invented can fully prevent the loss of neurons in the brain. Instead, Voyager’s gene therapy acts like a biological detour around dead neurons, so Parkinson’s patients respond better and longer to levodopa, the standard drug used to keep motor function under control.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy